Scientific References

Honing in on PARPi response in Prostate Cancer: from HR pathway- to gene-by-gene granularity
Alexandra O, et al. Clinical Cancer Research. May 1 2020 DOI: 10.1158/1078-0432.CCR-20-0707

Pan-cancer analysis of whole genomes.
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Nature. 2020; 578(7793):82–93. doi:10.1038/s41586-020-1969-6

Synthetic lethality as an engine for cancer drug target discovery.

Huang A, Garraway LA, Ashworth A, Weber B. Nat Rev Drug Discov. 2020;19(1):23–38

CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions.

Su D, Feng X, Colic M, et al. DNA Repair (Amst). 2020;87:102803.

A CRISPR Way to Identify Cancer Targets.

Hahn WC. N Engl J Med. 2019;380(25):2475–2477.

Synthetic lethality in lung cancer and translation to clinical therapies. 

Leung AW, de Silva T, Bally MB, Lockwood WW. Mol Cancer. 2016;15(1):61. Published 2016 Sep 29.

High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.

Hart T, Chandrashekhar M, Aregger M, et al. Cell. 2015;163(6):1515–1526.

The concept of synthetic lethality in the context of anticancer therapy. 

Kaelin WG Jr. Nat Rev Cancer. 2005;5(9):689–698.

Global mapping of the yeast genetic interaction network.

Tong AH, Lesage G, Bader GD, et al. Science. 2004;303(5659):808–813.